Drugs / Mitazalimab
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07319195 | Apr 2026 → Apr 2028 expected | breast cancer | Jennifer Zhang | Recruiting | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06205849 | Jul 2024 → Aug 2028 expected | malignant pancreatic neoplasm | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1 | NCT05650918 | Aug 2021 → May 2023 | malignant pancreatic neoplasm | Joachim Aerts, MD PhD | Completed | No outcome recorded |
| Phase 1 | NCT02829099 | Sep 2016 → Jul 2021 | high grade malignant neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02379741 | Apr 2015 → Mar 2017 | neoplasm | Alligator Bioscience AB | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04888312 | Sep 2021 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Alligator Bioscience AB | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07199764 | Nov 2025 → Oct 2027 expected | pancreatic ductal adenocarcinoma | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07437287 | Jul 2026 → Apr 2030 expected | biliary tract cancer | UNICANCER | Not yet recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitazalimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650918 ↗ |
| Known as | ADC-1013 | “The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent...” NCT05650918 ↗ |
| Known as | JNJ-64457107 | “The use of CD40 agonists (such as mitazalimab, also known as JNJ-64457107 and ADC-1013) may convert pancreatic adenocarcinomas into immunological hot tumors by T-cell-dependent...” NCT05650918 ↗ |
| Known as | JNJ-7107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297870 ↗ |
| Known as | Vanalimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297870 ↗ |
| Action | Activate | “agonistic human monoclonal IgG1 anti-CD40 antibody” NCT02379741 ↗ |
| Modality | Monoclonal antibody | “an agonistic human monoclonal IgG1 anti-CD40 antibody” NCT02379741 ↗ |
| Route | Other | “administered intratumorally (as repeated injections directly into the tumor tissue)” NCT02379741 ↗ |
| Target | CD40 | “anti-CD40 antibody” NCT02379741 ↗ |